OPK - OPKO Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305-575-4100
http://www.opko.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees5,690

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip FrostChairman & CEO971kN/A1936
Dr. Jane H. Hsiao M.B.A., Ph.D., MBAVice Chairman & Chief Technical Officer911kN/A1947
Mr. Adam E. LogalSr. VP, CFO, Chief Accounting Officer & Treasurer611k62.25k1978
Mr. Steven D. RubinExec. VP of Admin. & Director821kN/A1960
Ms. Kate InmanGen. Counsel & Sec.N/AN/A1973
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Corporate Governance

OPKO Health, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.